Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · With the funding of two startups this week, OrbiMed has passed Alexandria Venture Investments to become the third most active biotech investor since 2022, according to BioPharma Dive data.
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...
Incyte sinks on setback for drugs acquired in $750M buyout
Nov 19, 2024 · Incyte has already completed enrollment in other proof-of-concept studies of INCB000262 in atopic dermatitis and inducible urticaria. Data from those trials will guide future development of the drug as well as “back-up molecules,” the company said.
Pfizer to pull sickle cell drug from market, shut down trials
Sep 26, 2024 · Dive Insight: The withdrawal will remove one of the few treatment options for the millions of people around the world living with sickle cell disease, which causes severe pain and can lead to organ damage, stroke and death.. Oxbryta, a once-a-day tablet, was designed to reduce “sickling,” the warping of red blood cells that leaves them unable to …
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
Sep 27, 2024 · The clearance is expected to further boost sales of Dupixent, which is a key source of revenue for both Sanofi and Regeneron. Since first reaching the U.S. market in 2017 as a treatment for eczema, Dupixent has now been cleared for six other diseases.
Sanofi’s rare disease drug finds yet another home
Oct 4, 2024 · Enjaymo won U.S. approval in early 2022 after a winding journey. In 2014, the medicine was in development at San Francisco-based iPerian. But that year, Bristol Myers Squibb bought the company for its work in neurodegenerative diseases. iPerian’s programs targeting the immune system were spun out into a new biotechnology firm, True North Therapeutics.